MERCK Kommanditgesellschaft auf Aktien (XETRA:MRK.DE)
| Market Cap | 60.00B+15.1% |
| Revenue (ttm) | 21.14B-0.4% |
| Net Income | 2.37B-17.2% |
| EPS | 5.45-17.2% |
| Shares Out | 434.46M |
| PE Ratio | 25.34 |
| Forward PE | 15.46 |
| Dividend | €2.20(1.59%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 47,239 |
| Open | 138.25 |
| Previous Close | 140.15 |
| Day's Range | 137.55 - 138.75 |
| 52-Week Range | 100.70 - 148.80 |
| Beta | 0.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About MRK.DE
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MRK.DE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MRK.DE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MRK.DE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MRK.DE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MRK.DE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MRK.DE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MRK.DE
| ETF | Est. Holding Size |
|---|---|
| VXUSVanguard Total International Stock ETF | $307.82M |
| VEAVanguard FTSE Developed Markets ETF | $204.19M |
| IEFAiShares Core MSCI EAFE ETF | $153.40M |
| EFAiShares MSCI EAFE ETF | $72.36M |
| EFViShares MSCI EAFE Value ETF | $56.93M |
| VGKVanguard FTSE Europe ETF | $50.13M |
Estimated from each fund’s disclosed top holdings × AUM
MRK.DE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MRK.DE’s recent data — informational, not investment advice
